| Preliminary Program subject to change | |||||||||
| 02B05 Polymorphism In Pharmaceutical Development | |||||||||
| Overview | Presentations are solicited for polymorphism of substances related to the development of active pharmaceutical ingredients. This includes methods for discovering and producing the most stable form. The impact of form selection on a reproducible manufacturing process for a stable drug substance or formulated drug product is also of interest. Papers which examine strategies/methodologies for the control of polymorphism during crystallization, drying, storage and formulation are most welcomed. This may include but is not limited to the affect of solvent composition, particle size, shear environment, seeding and reactor configuration. The novel use of process analytical technologies for monitoring and control of crystallizations is also an important component to be covered in this session. | ||||||||
| Primary Sponsor | Crystallization and Evaporation (02b) | ||||||||
| Co-Sponsor(s) | Pharmaceuticals (15b) | ||||||||
ChairThomas LaPortePharmaceutical Research Institute Bristol-Myers Squibb One Squibb Drive New Brunswick, NJ 08903 Phone Number: 732-227-7042 Fax Number: 732-227-3930 Email: thomas.laporte@bms.com
CoChairPriscilla J. HillAssistant Professor Mississippi State University Box 9595 Swalm School of Chemical Engineering Mississippi State, MS 39762 Phone Number: 662-325-8249 Fax Number: 662-325-2482 Email: phill@che.msstate.edu | |||||||||
| |||||||||